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To examine the in vivo eﬀects of the 15-member macrolide, azithromycin (AZM), on mucus hypersecretion, we induced
hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium by intranasal instillation of ovalbumin (OVA) in OVA-
sensitizedrats,orbyintranasallipopolysaccharides(LPS)instillation.OraladministrationofAZM(5–10mg/kg)orclarithromycin
(CAM, 5–10mg/kg) signiﬁcantly inhibited OVA- and LPS-induced mucus production, whereas josamycin (JM) or ampicillin
(ABPC) showed no eﬀect. In vitro eﬀects of AZM on airway epithelial cells were examined using NCI-H292 cells and human nasal
epithelial cells cultured in air-liquid interface. Mucus secretion was evaluated by enzyme-linked immunosorbent assay using an
anti-MUC5AC monoclonal antibody. AZM or CAM signiﬁcantly inhibited tumor necrosis factor-α (TNF-α) (20ng/mL)-induced
MUC5AC secretion from NCI-H292 cells at 10−6–10−7 M, whereas JM or ABPC showed no eﬀect. AZM signiﬁcantly inhibited
TNF-α (20ng/mL)-induced MUC5AC secretion from human nasal epithelial cells at 10−4 M. MUC5AC mRNA expression was
also signiﬁcantly inhibited. These results indicate that the 15-member macrolide, AZM, exerts direct inhibitory eﬀects on mucus
secretion from airway epithelial cells and that it may be useful for the treatment of mucus hypersecretion caused by allergic
inﬂammation and LPS stimulation.
1.Introduction
The 14-member macrolides, clarithromycin (CAM) and
erythromycin (EM), and the 15-member macrolide, azith-
romycin (AZM), are widely used for the treatment of airway
inﬂammation. Low-dose, long-term macrolide therapy has
been reported to be very eﬀective for patients with chronic
airway diseases, such as diﬀuse panbronchiolitis [1], chronic
bronchitis[2,3],andchronicrhinosinusitis[4,5].Ithasbeen
suggested that these eﬀects depend on anti-inﬂammatory
and immunomodulatory actions of 14- and 15-member
macrolides rather than antibacterial one.
Hypersecretion of mucus is an important characteristic
of these airway inﬂammations. The clinical eﬀectiveness of
macrolide therapy was represented by a signiﬁcant reduction
in the amount of secreted mucus. In our previous study,
oral administration of CAM or EM signiﬁcantly inhibited
lipopolysaccharides- (LPS-) induced and antigen-induced
mucus production in rat nasal epithelium, whereas 16-
member macrolide, josamycin (JM), showed no eﬀect. CAM
and EM also inhibited mucus secretion from cultured airway
epithelial cells, NCI-H292 cells, and human nasal epithelial
cells cultured in air-liquid interface [6, 7]. These results
indicatethatthe14-membermacrolides,CAMandEM,exert
direct inhibitory eﬀects on mucus secretion from airway
epithelial cells. However, the inhibitory eﬀect of 15-member
macrolide, AZM, on mucus secretion is less well studied
compared with CAM and EM.
In the present study, to demonstrate the eﬀects of AZM
on mucus secretion from airway epithelial cells, we evaluated
(1) the in vivo eﬀects of AZM on antigen-induced and
LPS-induced mucus production in rat nasal epithelium,
and (2) the in vitro eﬀects on tumor necrosis factor-α-
(TNF-α-) induced mucus secretion from human mucoepi-
dermoid carcinoma cells (NCI-H292 cells) and from human
nasal epithelial cells cultured in air-liquid interface. Mucus2 Mediators of Inﬂammation
secretion was evaluated by enzyme-linked immunosorbent
assay (ELISA) using an anti-MUC5AC monoclonal antibody
that recognizes peptide backbones of mucin. The eﬀect on
mRNA expression of MUC5AC gene was also examined.
2. Methods
2.1. Mucus Hypersecretion in Rat Nasal Epithelium. All
experiments were approved by the Committee for the Care
and Use of Laboratory Animals of Mie University School of
Medicine.Sensitizationandchallengeofratswereperformed
as previously reported [8]. Male Fisher 344 rats (6 weeks
old)wereimmunizedwithintraperitonealinjectionof200μg
ovalbumin (OVA, grade V; Sigma Chemical Co., St. Louis,
MO) and 10mg of Al(OH)3 at days 1, 2, 3, and 11. At day
19, 0.1mL saline containing 10mg of OVA was instilled into
nasal cavity for 3 days. For LPS stimulation, rats (9 weeks
old) were intranasally instilled with 0.1mL saline containing
0.1mg LPS from Escherichia coli 0111:B4 (Sigma) for 3 days
[9].
AZM (5–10mg/kg, Pﬁzer Pharmaceutical, Tokyo), CAM
(5–10mg/kg, Taisho Pharmaceutical, Tokyo), JM (10mg/kg,
Yamanouchi Pharmaceutical, Tokyo), or ampicillin (ABPC,
30mg/kg, Sigma) in 0.5% carboxymethyl cellulose sodium
salt was given orally 1 hour before the intranasal instillation
of OVA or LPS for 3 days. Twenty-four hours after the last
intranasal instillation of OVA or LPS, rats were sacriﬁced,
and the nasal cavity was transversely sectioned at the level
of incisive papilla. Paraﬃn sections were stained with alcian
blue-periodic acid-Schiﬀ and hematoxylin (AB-PAS-H).
2.2. Morphometry. The percentage area of AB-PAS-stained
mucosubstance in the surface epithelium was determined
with the image analyzer (SP 500, Olympus, Tokyo) [9].
The area of nasal epithelium was outlined, and the image
analyzer determined the area of AB-PAS-stained mucosub-
stance within this reference area. The percentage area of
mucosubstance per epithelial area was calculated over 2mm
(1mm of each side of nasal septum ×2) of the basal lamina
at the center of septal cartilage. Since the measured area of
mucosubstance changes in the oblique section, the percent
area of mucosubstance was used as a parameter of intraepi-
thelial mucus production.
2.3.CellCultures. Ahumanmucoepidermoidcarcinomacell
line, NCI-H292, was grown on plastic dish in RPMI 1640
mediumcontaining10%fetalbovineserum,penicillinstrep-
tomycin (50U/mL-50μg/mL), and Hepes (25mM).
Human nasal epithelial cells were obtained from nasal
polyps from patients with chronic sinusitis. The dissociated
epithelial cells were cultured in a serum-free hormone sup-
plement medium according to a technique described previ-
ously [10]. An air-liquid interface was created when the cells
became conﬂuent, and the cultures were supplemented with
medium containing 5 × 10−8 M retinoic acid.
When the NCI-H292 cells become conﬂuent, or at the
14-day culture in the air-liquid interface of nasal epithelial
cells, tumor necrosis factor-α (TNF-α), and AZM, CAM,
JM, or ABPC was added to the culture medium (pH7.2)
for 24 hours, then the culture medium and total RNA were
collected.
2.4. ELISA. The culture medium were incubated at 40◦C
in a 96-well plate, until dry. Plates were blocked with 2%
BSA for 1 hour, and then incubated with 50μLo fm o u s e
monoclonal MUC5AC antibody (1:100) for 1 hour. The
w e l l sw e r ei n c u b a t e dw i t h1 0 0μL of horseradish peroxidase-
goat anti-mouse IgG conjugate (1:10,000) for 1 hour. Color
reaction was developed using 3,3 ,5,5 -tetramethylbenzidine
peroxidase solution. Absorbance was read at 450nm.
2.5. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNA was extracted from cultured cells, reverse
transcribed, then the cDNA was ampliﬁed by PCR using
the Superscript preampliﬁcation system kit (Gibco, Grand
Island, NY). The MUC5AC cDNA was ampliﬁed using
thesenseprimer5 -CACCAAATACGCCAACAAGAC-3  and
the antisense primer 5 -CAGGGCCACGCAGCCAGAGAA-
3 . The GAPDH cDNA was ampliﬁed using the sense
primer 5 -CCACCCATGGCAAATTCCATGGCA-3  and the
antisense primer 5 -TCTAGACGGCAGGTCAGGTCCACC-
3 .
2.6. Statistics. All data are expressed as mean ± SD. The
diﬀerence between variables was analyzed by the Mann-
Whitney U test. Probability values of P<0.05 were consid-
ered signiﬁcant.
3. Results
3.1. In Vivo Eﬀects on Mucus Production. Intranasal instil-
lation of OVA for 3 consecutive days induced hypertrophic
and metaplastic changes of goblet cells in nasal septal
epithelium of OVA-sensitized rats. Similar changes of goblet
cells occurred after 3 days of LPS instillation. Only a few
goblet cells were observed in control groups (untreated
control, saline-instilled, and sham-sensitized rats challenged
with saline or OVA, and OVA-sensitized rats challenged with
saline).
Oral administration of AZM (5–10mg/kg) or CAM (5–
10mg/kg) signiﬁcantly inhibited OVA-induced mucus pro-
duction,whereastreatmentwithJM(16-membermacrolide)
or ABPC showed no signiﬁcant eﬀect (Figure 1). OVA-
sensitized rats, challenged with OVA, showed signiﬁcant
inﬁltration of eosinophils in nasal septal mucosa, however,
AZM had no eﬀect on OVA-induced eosinophil inﬁltration.
The number of eosinophils in nasal septal mucosa/8mm
(4mm in each side ×2) was 2.6 ± 1.8 (saline control), 47.2 ±
17.7 (OVA-induced control), 51.4 ± 18.3 (AZM 5mg/kg),
and 44.4 ± 26,2 (AZM 10mg/kg). LPS-induced mucus pro-
ductionwasalsosigniﬁcantlyinhibitedbythetreatmentwith
AZM (10mg/kg) or CAM (10mg/kg), whereas JM or ABPC
showed no eﬀect (Figure 2).Mediators of Inﬂammation 3
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Figure 1:Eﬀectsofazithromycin(AZM,5–10mg/kg),clarithromy-
cin (CAM, 5–10mg/kg), josamycin (JM, 10mg/kg), or ampicillin
(ABPC, 30mg/kg) on OVA-induced mucus production in OVA-
sensitized rats (n = 6). Signiﬁcant increase in intraepithelial muco-
substance occurred 24 hours after 3 days of OVA instillation. Oral
administration of AZM or CAM signiﬁcantly inhibited antigen-
induced mucus production, whereas JM and ABPC had no eﬀect.
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Figure 2: Eﬀects of azithromycin (AZM, 10mg/kg), clarithromycin
(CAM, 10mg/kg), josamycin (JM, 10mg/kg), or ampicillin (ABPC,
30mg/kg) on LPS-induced mucus production in rat nasal epithe-
lium (n = 6). Signiﬁcant increase in intraepithelial mucosubstance
occurred 24 hours after 3 days of LPS instillation. Oral administra-
tion of AZM or CAM signiﬁcantly inhibited LPS-induced mucus
production, whereas JM and ABPC had no eﬀect.
3.2. In Vitro Eﬀects on Mucin Secretion
3.2.1. NCI-H292 Cells. TNF-α signiﬁcantly stimulated mu-
cin secretion from NCI-H292 cells. The percentage stim-
ulation of MUC5AC secretion was 44.0% ± 8.6%. AZM
showed an inhibitory eﬀect on TNF-α-induced MUC5AC
secretion at 10−6–10−8M. CAM (10−6–10−7M) also signif-
icantly inhibited TNF-α-induced mucin secretion, whereas
JM (16-member macrolide) and ABPC showed no eﬀects
(Figure 3).
3.2.2. Human Nasal Epithelial Cells. At the 14-day culture in
air-liquid interface condition, secretory cell diﬀerentiation
was induced in about 25% of cultured cells [10]. The
medium in the lower compartment did not react with
MUC5AC. Only the samples collected from the apical side
contained MUC5AC-reactive mucin, indicating that there
was a polarity in mucin secretion. TNF-α (20ng/mL) sig-
niﬁcantly stimulated MUC5AC secretion, and AZM signiﬁ-
cantly inhibited TNF-α-induced mucin secretion at 10−4 M
from cultured human nasal epithelial cells, whereas ABPC
showed no eﬀect. Changes of MUC5AC gene expression
were evaluated by RT-PCR, and AZM (10−4M) signiﬁcantly
inhibited MUC5AC mRNA expression of cultured human
nasal epithelial cells (Figure 4).
4. Discussion
In the present study, hypertrophic and metaplastic changes
of goblet cells were induced in rat nasal epithelium by
intranasal challenge with OVA in OVA-sensitized rats or by
intranasal LPS instillation. A similar increase of epithelial
mucosubstance occurred 24 hours after three days of OVA or
LPS instillation. Oral administration of AZM (15-member
macrolide) signiﬁcantly inhibited antigen- or LPS-induced
mucus production. These inhibitory eﬀects are similar with
CAM (14-member macrolide), whereas JM (16-member
macrolide) or ABPC showed no eﬀect. This is the ﬁrst report
showing the in vivo eﬀects of AZM on mucus production in
upper airways.
Mucus hypersecretion associated with hypertrophy and
metaplasia of epithelial secretory cells is a major characteris-
tic of chronic airway diseases, and the clinical eﬀectiveness
of low-dose and long-term treatment with 14-member
macrolides, CAM and EM, is represented by the signiﬁcant
reduction of the amount of secreted mucus, sputum, and
rhinorrhea. Tamaoki and coworkers [11] have reported that
erythromycin (EM) signiﬁcantly inhibited mucus secretion
in guinea pig trachea in vivo. In our previous studies [6, 7],
CAM and EM inhibited antigen- and LPS-induced mucus
production in rat nasal epithelium. CAM and EM showed
the direct inhibitory eﬀect on mucin secretion from cultured
airway epithelial cells [6].
The 15-member macrolide, AZM, also has an anti-
inﬂammatory action, and AZM has been widely used for
the treatment of patients with chronic airway inﬂammation,
such as cystic ﬁbrosis [12], chronic obstructive pulmonary
disease[13],andbronchiolitisobliteranssyndrome[14].The
meta-analysis study revealed that long-term use of AZM in
cystic ﬁbrosis patients improved the lung function, especially
for Pseudomonas aeruginosa-colonized patients [12]. A large
randomized placebo-controlled study revealed that long-
term use of AZM decreased the risk of acute exacerbations
of patients with chronic obstructive pulmonary diseases
[13].
Several animal studies demonstrated that AZM atten-
uated many types of experimental airway inﬂammation
caused by the allergic inﬂammation [15], by the inhalation
of irritant gas, ozone [16], by the lung ischemia reperfusion
injury [17], or by bacterial and viral infections [18, 19]4 Mediators of Inﬂammation
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Figure 4: Eﬀects of azithromycin (AZM) and ampicillin (ABPC) on TNF-α (20ng/mL)-induced mucin secretion (a) and MUC5AC mRNA
expression (b) from human nasal epithelial cells cultured at air-liquid interface (n = 5).(a) TNF-αstimulated MUC5ACsecretion, and AZM
signiﬁcantly inhibited TNF-α-induced mucin secretion at 10−4 M, whereas ABPC showed no eﬀect. (b) Total RNA was isolated and analyzed
for MUC5AC and GAPDH mRNA expression by RT-PCR (n = 5). AZM signiﬁcantly inhibited MUC5AC mRNA expression at 10−4 Ma s
demonstrated by the MUC5AC/GAPDH ratio.
in lower airways. In the present study, AZM also atten-
uated antigen- or LPS-induced mucus production in rat
nasal epithelium. Many investigators demonstrated the anti-
inﬂammatory action of AZM, which includes the immun-
omodulatory eﬀects on inﬂammatory cells [19, 20], the
modulation of cytokine production [21], and the inhibition
of bacterial function and bioﬁlm formation [22].
Recently, several in vitro studies have demonstrated
the inhibitory eﬀects of AZM on mucus secretion from
airway epithelium. AZM inhibited MUC5AC expression and
secretion from NCI-H292 cells, induced by human neu-
trophil peptide-1 and LPS [23], by Pseudomonas aeruginosa-
derived N-(3-Oxododecanoyl) homoserine lactone [24], or
by nontypable Haemophilus inﬂuenza and ChlamydophiliaMediators of Inﬂammation 5
pneumoniae [25, 26]. AZM inhibited acetylcholine-induced
MUC5AC release from swine airway submucosal gland cells
[27]. In the present study, we examined the TNF-α-induced
MUC5AC secretion from airway epithelial cells. TNF-α
has been implicated in LPS-induced airway inﬂammation.
LPS stimulation enhanced the TNF-α/β generation in rat
lung [28], and TNF-α antagonist inhibited the LPS-induced
mucus hypersecretion in rat nasal epithelium [29]. We
found that AZM and CAM signiﬁcantly inhibited TNF-α-
induced MUC5AC secretion from NCI-H292 cells. AZM
also inhibited mucin secretion from human nasal epithelial
cells cultured in air-liquid interface, and MUC5AC mRNA
expression was signiﬁcantly inhibited. This is the ﬁrst
report showing the inhibitory eﬀects of AZM on mucus
secretion from normal human airway epithelial cells. These
inhibitory actions appeared to be unique for 14- and
15-member macrolides because other antibiotics, JM (16-
member macrolide) and ABPC, did not show any eﬀect.
In our previous study, the active concentrations of CAM
and EM for the inhibition of mucin secretion are 10−6
to 10−7 M for NCI-H292 cells and 10−4 to 10−5 Mf o r
human nasal epithelial cells [6]. The diﬀerent results may be
caused by the diﬀerent responses between mucoepidermoid
carcinoma cells and normal nasal epithelial cells. In the
present study, AZM showed the similar inhibitory eﬀect on
MUC5AC secretion from NCI-H292 cells and from human
nasal epithelial cells. It is well known that the macrolide
antibiotics achieve higher concentration in airway tissues,
and the therapeutic concentrations are 10−5 to 10−6 Mi n
tissues. In our in vivo study, oral administration of 5–
10mg/kg AZM or CAM signiﬁcantly inhibited epithelial
mucus production, and a previous study demonstrated that
this is comparable with tissue concentration of 10−5 to
10−6 Mi nr a t s[ 30]. These results indicate that the in vivo
eﬀect of AZM or CAM is caused in some parts by the direct
inhibitory eﬀect on mucus secretion from the epithelial cells.
5. Conclusion
We have induced hypertrophic and metaplastic changes of
goblet cells in rat nasal epithelium by intranasal challenge
with OVA in OVA-sensitized rat and by LPS instillation,
and we have demonstrated in this model that AZM inhibits
epithelial mucus production produced by allergic inﬂamma-
tion and by LPS stimulation. We have also demonstrated that
AZM directly inhibits MUC5AC secretion from NCI-H292
cells and human nasal epithelial cells. These novel ﬁndings
may explain the clinical eﬃcacy of AZM in patients with
chronic airway inﬂammation.
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